Tesamorelin vs Ipamorelin
Tesamorelin has FDA-reviewed VAT trials for its narrow HIV-lipodystrophy indication; ipamorelin has a separate postoperative-ileus study without established benefit for that outcome.
Last updated: September 29, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Tesamorelin
Dossier overview
Ipamorelin
Dossier overview
Compare endpoints before compounds
Tesamorelin’s FDA label covers reduction of excess abdominal fat in adults with HIV and lipodystrophy. Its phase 3 studies measured VAT, not a general weight-loss or anti-aging outcome. The label states long-term cardiovascular safety is unknown. FDA prescribing information; Falutz et al., 2007, PMID 18057338.
Ipamorelin is a ghrelin-receptor agonist rather than a GHRH analog. A phase 2 randomized proof-of-concept study enrolled 117 bowel-resection patients to assess postoperative ileus. The median first-tolerated-meal times differed numerically, but the reported comparison was not statistically significant (p = 0.15). This is neither a VAT trial nor proof of benefit for general body composition. Beck et al., 2014, PMID 25331030.
| Question | Tesamorelin | Ipamorelin |
|---|---|---|
| Evidence grade for cited clinical outcome | High for VAT reduction in indicated adults | Low for established patient benefit in the cited postoperative study |
| Trial population | Adults with HIV and excess abdominal fat | Patients following bowel resection |
| FDA status | Approved for its labeled indication | No approved indication established in FDA’s cited review |
| Safety interpretation | Label warnings and unknown long-term cardiovascular safety | Limited route-specific human safety data; no blanket safe/unsafe conclusion |
FDA’s ipamorelin compounding review notes serious adverse events, including deaths, in the intravenous postoperative study and insufficient safety information for certain other injectable routes. A bulk-substance or compounding assessment is not an FDA product approval. FDA compounding safety review.
No cited direct trial compares tesamorelin with ipamorelin, and mechanistic differences do not establish a treatment ranking or combination safety.
Educational comparison only; not medical advice.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.